Literature DB >> 19156392

[Multidisciplinary treatment for adult soft tissue sarcoma].

F Lordick1.   

Abstract

The current standard in local treatment of soft tissue sarcomas has shifted from amputation and similar mutilating resections to more organ- and function-preserving surgery. This was possible through multidisciplinary treatment approaches, particularly those including adjuvant radiation therapy. Adjuvant radiation showed significant improvement in local tumour control after resection with tight margins and in high-risk sarcomas. Unfortunately adjuvant radiation failed to improve overall survival. Perioperative chemotherapies also have not contributed to improvement in the overall prognosis worldwide. Progress may occur when the pathogenesis and molecular profile of specific sarcoma subtypes are better understood, allowing more effective new drugs. One example is the treatment of advanced gastrointestinal stromal tumour with imatinib, a small molecular kinase inhibitor of the c-kit receptor. Presently the most effective measure to improve the prognosis with soft tissue sarcomas is early patient referral to expert centres, where diagnostic workup and therapy decisions are made on a multidisciplinary basis and updated according to the newest guidelines and study results.

Entities:  

Mesh:

Year:  2009        PMID: 19156392     DOI: 10.1007/s00104-008-1597-4

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  43 in total

1.  Desmoid tumors respond to chemotherapy: defying the dogma in oncology.

Authors:  Shreyaskumar R Patel; Robert S Benjamin
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

Review 2.  Evidence-based recommendations for local therapy for soft tissue sarcomas.

Authors:  Peter W T Pisters; Brian O'Sullivan; Robert G Maki
Journal:  J Clin Oncol       Date:  2007-03-10       Impact factor: 44.544

Review 3.  State-of-the-art approach in selective curable tumours: soft tissue sarcoma.

Authors:  I Judson
Journal:  Ann Oncol       Date:  2008-09       Impact factor: 32.976

4.  Postoperative nomogram for 12-year sarcoma-specific death.

Authors:  Michael W Kattan; Denis H Y Leung; Murray F Brennan
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

5.  A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.

Authors:  Xavier Garcia del Muro; Antonio Lopez-Pousa; Javier Martin; Jose M Buesa; Javier Martinez-Trufero; Antonio Casado; Andres Poveda; Josefina Cruz; Isabel Bover; Joan Maurel
Journal:  Cancer       Date:  2005-10-15       Impact factor: 6.860

6.  Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?

Authors:  S Bonvalot; A Laplanche; F Lejeune; E Stoeckle; C Le Péchoux; D Vanel; P Terrier; J Lumbroso; M Ricard; G Antoni; A Cavalcanti; C Robert; N Lassau; J Y Blay; A Le Cesne
Journal:  Ann Oncol       Date:  2005-06-01       Impact factor: 32.976

7.  The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience.

Authors:  T Wiklund; G Saeter; H Strander; T Alvegård; C Blomqvist
Journal:  Eur J Cancer       Date:  1997-03       Impact factor: 9.162

8.  Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.

Authors:  R Palumbo; S Palmeri; M Antimi; C Gatti; P Raffo; G Villani; S Toma
Journal:  Ann Oncol       Date:  1997-11       Impact factor: 32.976

9.  Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.

Authors:  Michael C Heinrich; Heikki Joensuu; George D Demetri; Christopher L Corless; Jane Apperley; Jonathan A Fletcher; Denis Soulieres; Stephan Dirnhofer; Amy Harlow; Ajia Town; Arin McKinley; Shane G Supple; John Seymour; Lilla Di Scala; Allan van Oosterom; Richard Herrmann; Zariana Nikolova; And Grant McArthur
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

10.  Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  D Joshi; James R Anderson; C Paidas; J Breneman; D M Parham; W Crist
Journal:  Pediatr Blood Cancer       Date:  2004-01       Impact factor: 3.167

View more
  1 in total

1.  [Surgical margins in soft tissue sarcoma of the extremities].

Authors:  H-U Steinau; L Steinsträsser; S Langer; I Stricker; O Goertz
Journal:  Pathologe       Date:  2011-02       Impact factor: 1.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.